Abstract:While protein coronas (PCs) are an important barrier in the clinical application of nanomedicines, the specific effects of PCs on nanoparticles (NPs) in vivo are unclear. Herein, we demonstrated that PCs from clinical sources greatly influenced the active targeting capacities of transferrin-modified NPs (Tf-NPs). Compared to PCs from healthy volunteers, PCs from the plasma of patients with nonsmall cell lung cancer (NSCLC) decreased the A549 uptake of Tf-NPs to a greater degree. The PC proteome revealed that this difference may be mediated by certain proteins in plasma. To attenuate the negative influence of PCs from patients, precoating Tf-NPs with PCs derived from healthy mice significantly enhanced active targeting capacities. Paclitaxel-loaded Tf-NPs with PCs derived from healthy mice showed the strongest antitumor effects in mice with NSCLC. This work illustrates the influence of PCs of ligand-modified NPs in clinical practice and proposes the use of corona-enabled active targeting for precision nanomedicine.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.nanolett.0c03982?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.nanolett.0c03982</a>.Details related to materials and methods; characterization of particle size and zeta (ζ) potential of bare NPs and NPs with PC (Table S1); the amount of protein adsorbed on NPs (Table S2); the most abundant proteins (top 30) identified in the PC of NPs from human sources (Table S3); the most abundant proteins (top 30) identified in the PC of NPs from murine sources (Table S4); microscopic observation of coumarin+ A549 cells (Figures S1 and S3); normalized fluorescence intensity in A549 cells (Figures S2 and S4); schematic description of the experimental design for studies of in vivo mouse PC formation (Figure S5); the intensity diameter distribution of NPs with/without in vivo mouse-derived PC (Figure S6); TEM images of NPs with/without in vivo mouse-derived PC (Figure S7); microscopy observation of coumarin+ LL/2 cells (Figures S8 and S10); the normalized fluorescence intensity in LL/2 cells (Figures S9 and S11); fluorescence intensity in organs and tumor 24 h post-injection (Figure S12); tumor size in all mouse groups (Figure S13); coomassie brilliant blue-stained SDS-PAGE gel of PCs associated with NPs (Figure S14); classification of PCs according to physiological function (Figure S15); Venn diagrams depicting the number of unique proteins identified in the in vitro-formed coronas and their respective overlap (Figure S16); Venn diagrams depicting the number of unique proteins identified in the in vivo-formed coronas and their respective overlap (Figure S17); and evaluation of NP safety and IgE concentrations in serum from all murine groups (Figure S18) (<a class="ext-link" href="/doi/suppl/10.1021/acs.nanolett.0c03982/suppl_file/nl0c03982_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function

Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro

Lipidomic Analysis Probes Lipid Coronas on Hydrophilic Nanoparticles from Natural Lung Surfactant

Impact of Protein Coronas on Lipid Nanoparticle Uptake and Endocytic Pathways in Cells

Unraveling the impact of different liposomal formulations on the plasma protein corona composition might give hints on the targeting capability of nanoparticles

Lipid Nanoparticle (LNP) Chemistry Can Endow Unique in Vivo RNA Delivery Fates Within the Liver That Alter Therapeutic Outcomes in a Cancer Model

The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy.

A magnetic separation method for isolating and characterizing the biomolecular corona of lipid nanoparticles

Universal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery

Physicochemical and biological characterization of the lipid particles with bovine serum albumin corona

Multiparametric Approach For The Evaluation Of Lipid Nanoparticles For Sirna Delivery

Looking back, moving forward: protein corona of lipid nanoparticles

Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood.

Protein Coronas Derived from Cerebrospinal Fluid Enhance the Interactions Between Nanoparticles and Brain Cells

Cholesterol modulates the physiological response to nanoparticles by changing the composition of protein corona

Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics

Protein corona of nanoparticles: distinct proteins regulate the cellular uptake.

Protein corona: implications for nanoparticle interactions with pulmonary cells

Physiological Barriers and Strategies of Lipid‐based Nanoparticles for Nucleic Acid Drug Delivery

Nanoparticles Based on Natural Lipids Reveal Extent of Impacts of Designed Physical Characteristics on Biological Functions

Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles